Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Says China Trial Started for Claudin 18.2 CAR-T Cell Therapy

publication date: Feb 21, 2022

Innovent Biologics reported the first patient has been dosed in a China trial of its universal modular Claudin 18.2-targeting CAR-T cell product. The study is an investigator-initiated clinical trial that will test IBI345 in patients with Claudin18.2-positive solid tumors. IBI345 is the first product to emerge from Innovent's $2 billion CAR-T collaboration with Roche, announced two years ago. Roche is doing the discovery work on CAR-T candidates, while Innovent is in charge of conducting clinical trials. Roche holds an option to in-license ex-China rights to the products. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.